Optimal management of atopic dermatitis in infancy.
The necessity to optimise the management of atopic dermatitis of infants needs knowledge of three components: increase of prevalence, extreme frequency of food allergy and increase in the frequency of the syndrome of multiple allergies, that frequently develops into asthmatic disease. Management of DA in infancy (first year of life) is based on the global strategy of understanding the physiological Th2 polarisation at birth, that does not allow a re-equilibration of the Th1-Th2 balance that progresses in the first six months of life (in normal infants) making in this period a window of opportunity for sensitizations. Prevention in high-risk children (familial history of atopy) covers the non-exposure to in door pollutants (tobacco and volatile organic compounds), breast-feeding or a hypoallergenic formula for a hydrolysate of pork and soya proteins or better an extensive hydrolysate of casein. Four situations require moving to an amino acid substitute: failure to thrive, severe atopic dermatitis, a syndrome of multiple food allergies, allergy to hydrolysates. Reintroduction of foods should be considered with the least delay so as to induce digestive tolerance. It should take into account the clinical development, the intensity of the sensitisation and eventually depend on a realistic test of introduction. Management of DA searches for recovery of generalized eczema, failure to immediate improvement of quality of life prevention of immediate complications (local sepsis) acceleration of return to food tolerance. Prevention of ulterior development of asthma by immediately introducing measures to diminish respiratory exposure to allergens and tobacco is hoped for.
Moneret-Vautrin
D A
DA
Department of Internal Medicine, Clinical Immunology and Allergology University Hospital, av. de Lattre de Tassigny, 54035 Nancy, France.
D000328:Adult; D001249:Asthma / Q000517:prevention & control; D001942:Breast Feeding / Q000009:adverse effects; D003876:Dermatitis, Atopic / Q000150:complications / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D004785:Environmental Pollutants / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000276:immunology; D005512:Food Hypersensitivity / Q000150:complications / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007225:Infant Food / Q000009:adverse effects; D018655:Lymphocyte Count; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D015995:Prevalence; D012307:Risk Factors; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014028:Tobacco Smoke Pollution / Q000009:adverse effects
D004785:Environmental Pollutants; D014028:Tobacco Smoke Pollution